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Abstract: Cancers have the ability to develop resistance to traditional therapies, and the 
increasing  prevalence  of  these  drug  resistant  cancers  necessitates  further  research  and 
treatment  development.  This  paper  outlines  the  current  knowledge  of  mechanisms  that 
promote or enable drug resistance, such as drug inactivation, drug target alteration, drug 
efflux,  DNA  damage  repair,  cell  death  inhibition,  and  the  epithelial-mesenchymal 
transition, as well as how inherent tumor cell heterogeneity plays a role in drug resistance. 
It also describes the epigenetic modifications that can induce drug resistance and considers 
how such epigenetic factors may contribute to the development of cancer progenitor cells, 
which are not killed by conventional cancer therapies. Lastly, this review concludes with a 
discussion on the best treatment options for existing drug resistant cancers, ways to prevent 
the formation of drug resistant cancers and cancer progenitor cells, and future directions  
of study. 
Keywords:  cancer;  drug  resistance;  epigenetics;  methylation;  cancer  progenitor  cells; 
combination therapy; review 
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Abbreviations 
EMT  epithelial-mesenchymal transition 
AraC  cytarabine 
CYP  cytochrome p450 
GST  glutathione-S-transferase 
UGT  uridine diphospho-glucuronosyltransferase 
TP53  tumor protein p53 
Apaf-1  apoptotic protease activating factor 1 
MAPK  mitogen-activated protein kinase 
EGFR  epidermal growth factor receptor 
HER2  human epidermal growth factor receptor 2 
TS  thymidylate synthase 
FdUMP  fluorodeoxyuridine monophosphate 
CH2THF 5,10-methylenetetrahydrofolate 
PTEN  phosphatase and tensin homolog 
IGF1R  insulin-like growth factor 1 receptor 
CML  chronic myeloid leukemia 
BCR-ABL break point cluster-Abelson 
Pgp  P-glycoprotein 
ER  estrogen receptor 
ABC  ATP-binding cassette 
MDR1  multidrug resistance protein 1 
MRP1  multidrug resistance-associated protein 1 
BCRP  breast cancer resistance protein 
ERK  extracellular signal-regulated kinases 
DDR  DNA damage response 
MGMT  O6-methylguanine DNA methyltransferase 
BCL-2  B-cell lymphoma 2 
TRAIL  tumor necrosis factor related apoptosis-inducing ligand 
HDACi  histone deacetylase inhibitors 
hMLH1  human mutL homolog 1 
DAC  2'-deoxy-5-azacytiding 
RFC  reduced folate carrier 
1. Introduction 
Drug  resistance  is  a  well-known  phenomenon  that  results  when  diseases  become  tolerant  to 
pharmaceutical  treatments.  This  concept  was  first  considered  when  bacteria  became  resistant  to  
certain antibiotics, but since then similar mechanisms have been found to occur in other diseases, 
including cancer. Some methods of drug resistance are disease-specific, while others, such as drug 
efflux, which is observed in microbes and human drug-resistant cancers, are evolutionarily conserved. 
Although many types of cancers are initially susceptible to chemotherapy, over time they can develop 
resistance through these and other mechanisms, such as DNA mutations and metabolic changes that 
promote drug inhibition and degradation. In this review, we outline how drug resistance via drug 
inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, and the Cancers 2014, 6  1771 
 
epithelial-mesenchymal transition (EMT) develops in cancer in response to current treatments and how 
these problems are being addressed (Figure 1). We also consider how the cell heterogeneity inherent in 
cancerous  tumors  is  involved  in  the  development  of  drug  resistance.  Lastly,  we  conclude  with  a 
discussion on the emerging topic of epigenetics—how it contributes to drug resistance in cancer and  
its possible role in the development of cancer progenitor cells which are not killed by conventional 
cancer therapies. 
Figure 1. Categories of mechanisms that can enable or promote direct or indirect drug 
resistance  in  human  cancer  cells.  These  mechanisms  can  act  independently  or  in 
combination and through various signal transduction pathways. 
 
2. Drug Resistance in Cancer 
2.1. Drug Inactivation 
Drug activation in vivo involves complex mechanisms in which substances interact with different 
proteins. These interactions can modify, partially degrade, or complex the drug with other molecules or 
proteins, ultimately leading to its activation. Many anticancer drugs must undergo metabolic activation 
in  order  to  acquire  clinical  efficacy.  However,  cancer  cells  can  also  develop  resistance  to  such 
treatments through decreased drug activation. One example of this is observed in the treatment of acute 
myelogenous  leukemia  with  cytarabine  (AraC),  a  nucleoside  drug  that  is  activated  after  multiple 
phosphorylation events that convert it to AraC-triphosphate [1,2]. Down-regulation or mutation in this 
pathway can produce a decrease in the activation of AraC, and this can lead to AraC drug resistance. 
Other important examples of drug activation and inactivation include the cytochrome P450 (CYP) 
system, glutathione-S-transferase (GST) superfamily, and uridine diphospho-glucuronosyltransferase 
(UGT) superfamily [3]. 
The CYP system is generally divided into two classes. Class I is composed of CYP1A1, CYP1A2, 
CYP2E1, and CYP3A4, which are well conserved, do not have important functional polymorphisms, 
and are active in the metabolism of drugs and procarcinogens. Class II is composed of CYP2B6, 
CYP2C9, CYP2C19, and CYP2D6, which are highly polymorphic and active in drug metabolism but 
not in procarcinogen metabolism [4]. Because class II gene sequences are more variable than those of 
class I, these CYP are better suited for drug metabolism and may have a role in the development of Cancers 2014, 6  1772 
 
drug resistance in cancer. On the other hand, CYP1A1 and CYP1A2 metabolize procarcinogens into 
carcinogenic forms in the liver, and most anticancer drugs are metabolized by this method. Although 
CYP polymorphisms have not yet been associated with carcinogenesis, it is possible that mutations or 
alterations  in  CYP  may  change  these  proteins’  metabolic  capabilities,  such  as  increasing  the 
breakdown of drugs and their secretion by the kidneys [5]. In this case, the drug would not maintain 
proper levels in the patient, and the cancer would therefore be considered resistant to it. The use of 
CYP and their suspected role in carcinogenesis has been well studied [3,6]. 
Many anticancer drugs require metabolic activation, and thus cancer cells can develop resistance 
through decreased drug activation. In patients with advanced ovarian cancer, treatment with platinum 
and taxane-based chemotherapy is applied post-operatively. One way resistance to platinum can occur 
is  through  drug  inactivation  by  methallothionein  and  thiol  glutathione,  which  activate  the 
detoxification system [7]. Changes to apoptosis-related proteins can also result in drug resistance. For 
instance,  apoptosis  is  promoted  by  the  tumor  suppressor  protein  p53  (TP53),  in  response  to 
chemotherapy. TP53 is mutated in 50% of cancers [8], and when mutation or deletion of this gene 
renders it non-functional, drug resistance can follow [9]. Alternatively, inactivation of P53 regulators, 
such as caspase-9 and its cofactor, apoptotic protease activating factor 1 (Apaf-1), can also lead to drug 
resistance [10]. 
Another important example of drug activation and inactivation is observed in the GST superfamily, 
which  is  a  group  of  detoxifying  enzymes  that  function  to  protect  cellular  macromolecules  from 
electrophilic compounds. GSTs assist in the development of drug resistance through direct detoxification 
and  by  inhibiting  the  mitogen-activated  protein  kinase  (MAPK)  pathway  [11].  Elevation  of  GST 
expression  in  cancer  cells  enhances  detoxification  of  the  anticancer  drugs,  which  results  in  less 
efficient  cytotoxic  damage  of  the  cells  [12].  This  increase  is  also  associated  with  resistance  to 
apoptosis initiated by a variety of stimuli [13]. 
Lastly, the UGT superfamily is a group of enzymes that catalyze glucuronidation. This process 
regulates the formation of inactive hydrophilic glucuronides with substrates such as steroids, bile acids, 
and xenobiotics including environmental carcinogens and cytotoxics. The UGT1 and UGT2 genes code 
17 functional UGTs in humans, and these genes provide many tissues, such as the skin, breast, prostate 
gland, gut, and placenta, with a first line of metabolic defense from pathogenic substrates. However, 
widespread  down-regulation  of  UGT1A1  transcription  and  microsomal  activity  occurs  in  certain 
cancerous  states  [3].  The  expression  of  UGT1A1  is  negatively  regulated  by  DNA  methylation  at  
its  promoter  region,  and  irinotecan,  a  topoisomerase  I  inhibitor,  is  functional  when  this  gene  is  
silenced [14,15]. However, epigenetic changes that increase UGT1A1 expression may enable resistance 
to irinotecan and other drugs. Overall, drug inactivation is a mechanism of cancer drug resistance that 
warrants further investigation. 
2.2. Alteration of Drug Targets 
A  drug’s  efficacy  is  influenced  by  its  molecular  target  and  alterations  of  this  target,  such  as 
mutations  or  modifications  of  expression  levels.  In  cancers,  these  types  of  target  alterations  can 
ultimately lead to drug resistance. For example, certain anticancer drugs target topoisomerase II, an 
enzyme that prevents DNA from becoming super- or under-coiled. The complex between DNA and Cancers 2014, 6  1773 
 
topoisomerase II is usually transient, but these drugs stabilize it, leading to DNA damage, inhibition of 
DNA  synthesis,  and  a  halting  of  mitotic  processes.  Cancer  cells  can  confer  resistance  in  these 
circumstances  through  various  means.  Certain  cell  lines  have  become  resistant  to  topoisomerase  
II-inhibiting drugs through mutations in the topoisomerase II gene [16–18]. Another type of anticancer 
drug  targets  signaling  kinases,  such  as  members  of  the  epidermal  growth  factor  receptor  (EGFR) 
family and down-stream signaling partners such as Ras, Src, Raf, and MEK. Several of these kinases 
are  constitutively  active  in  certain  cancers,  and  this  promotes  uncontrolled  cell  growth.  In  most 
circumstances,  mutations  cause  the  over-activation  of  these  kinases;  however,  the  same  effect 
sometimes results from gene over-expression. Human epidermal growth factor receptor 2 (HER2), a 
receptor tyrosine kinase in the EGFR family, is overexpressed in 30% of breast cancer patients [14], 
and  drug  resistance  can  result  after  long  term  use  of  inhibitors  targeting  this  kinase  [19,20].  The 
increased response rates to EGFR inhibitors in certain lung cancers with EGFR tyrosine kinase domain 
mutations  are  reported  with  acquired  resistance  within  one  year.  An  EGFR-T790M  gatekeeper 
mutation was reported in half of all cases [21,22]. Other genetic alterations such as chromosomal 
rearrangements  and  mutations  in  anaplastic  lymphoma  kinase  are  seen  in  anaplastic  large-cell 
lymphoma [14,23]. Finally, resistance to paclitaxel and other taxanes has been observed in ovarian 
cancers via drug target alterations such as mutations in beta-tubulin, among other means [7]. 
Modified enzyme expression levels at drug target sites can also alter drug responses in cancer cells. 
For  example,  thymidylate  synthase  (TS)  inhibitors,  such  as  fluorouracil,  ultimately  inhibit  the 
transcription  of  TS  [14].  Fluorouracil  becomes  active  when  it  is  converted  to  fluorodeoxyuridine 
monophosphate (FdUMP), which forms a stable complex with TS and 5,10-methylenetetrahydrofolate 
(CH2THF).  This  TS-FdUMP-CH2THF  complex  results  in  a  slowly  reversible  inactivation  of  the 
enzyme [24]. Another example of drug target alteration has been observed in the androgen receptor. In 
about 30% of prostate cancers, the androgen receptor is genomically amplified, which enables these 
cancers  to  become  resistant  to  androgen  deprivation  therapy  with  the  drugs  leuprolide  and 
bicalutamide  [14,25].  These  drugs  cannot  inhibit  all  the  molecular  targets  present,  and  thus  these 
cancers are considered resistant to them. 
In addition to the changes in specific drug targets, drug resistance is also achieved by alteration  
in  the  signal  transduction  process  that  mediates  drug  activation.  For  example,  the  treatment  of  
HER2-positive  breast  cancer  tumors  with  trastuzumab  (Herceptin),  a  humanized  monocolonal 
antibody, has had high levels of efficacy in combination with chemotherapy. However, many patients 
who  initially  respond  to  trastuzumab  develop  resistance  and  relapse,  despite  continued  treatment. 
Trastuzumab also has limited efficacy as a single agent, and some patients do not respond to treatment 
at all, despite being HER2-positive. The mechanism of resistance is thought to be associated with cell 
cycle inhibition, co-expression of growth factor receptors, activation of PI3K/Akt pathway, and loss of 
phosphatase  and  tensin  homolog  (PTEN)  function  [26,27].  Insulin-like  growth  factor  1  receptor 
(IGF1R)  levels  have  been  found  to  significantly  increase  in  the  trastuzumab-resistant  cell  line  as 
compared to the non-resistant parental cell line. These results confirm that IGF1R inhibition improves 
response to trastuzumab in HER2-positive breast cancer cells, and suggest that dual targeting of IGF1R 
and  HER2  may  improve  response  in  HER2-positive  tumors  [28].  Others  have  also  shown  that 
activation of the PI3K/Akt pathway through PI3KCA mutations, PTEN loss, or both is associated with Cancers 2014, 6  1774 
 
accelerated disease progression and decreased survival, indicating the adverse effect of this pathway’s 
status on trastuzumab efficacy [29]. 
In the case of chronic myeloid leukemia (CML), break point cluster-Abelson (BCR-ABL) tyrosine 
kinase is generated from the chromosomal translocation t(9;22). Imatinib is a tyrosine kinase inhibitor 
that  specifically  targets  the  BCR-ABL  protein  and  induces  remission  in  patients  with  CML. 
Unfortunately, the majority of CML patients treated with imatinib develop resistance at some point 
during therapy. Some patients may fail to respond to initial treatment with imatinib (primary resistance), 
while others stop responding with prolonged therapy after an initial response (acquired resistance). 
Several  mechanisms  of  imatinib  resistance  have  been  proposed  that  account  for  loss  of  imatinib 
efficacy in patients with CML. Imatinib resistance can be caused by point mutations in the ABL gene
 
and  amplification  of  the  BCR-ABL  fusion  gene  [30].  In  addition  to  these  BCR-ABL-dependent 
mechanisms, BCR-ABL-independent mechanisms of imatinib resistance have been proposed, which 
involve  drug  transporter  and  signaling  cascades.  Investigation  of  SOCS-3  gene  methylation  and 
downstream effects in BCR-ABL-positive CML cells resistant to imatinib found that this epigenetic 
effect resulted in STAT3 protein activation that led to uncontrolled cell proliferation [31]. Others 
proposed that over-expression of the efflux drug transporter P-glycoprotein (Pgp) partially contributed 
to  imatinib  resistance  in  imatinib-resistant  K562  CML  cells  having  no  BCR-ABL  mutations  [32]. 
Additionally,  researchers  have  determined  that  the  BCR-ABL-independent  activation  of  ERK1/2 
contributes to imatinib resistance in K562/R cells and that ERK1/2 could be targeted for treatment in 
CML patients with imatinib resistance due to this mechanism [33]. 
Another example of alterations in signaling mechanisms is tamoxifen resistance in breast cancer. 
Tamoxifen  acts  as  an  estrogen  receptor  (ER)  antagonist.  However,  ER  signaling  has  a  complex 
interaction with other growth signaling pathways in breast cancer cells, thus enabling drug resistance 
through various mechanisms. For example, in tumors with active growth factor receptor signaling  
(e.g.,  HER2  amplification),  tamoxifen  may  lose  its  estrogen  antagonist  activity  and  acquire  more 
agonist-like activity, resulting in tumor growth stimulation [34]. Additionally, expression of EGFR and 
HER2, which are barely detected in control estrogen-treated tumors, was found to increase slightly 
with tamoxifen and markedly increase when tumors became resistant [35]. Understanding this and 
other methods of drug target alteration is important for diagnosing and developing new therapies to 
treat drug-resistant cancers. 
2.3. Drug Efflux 
One of the most studied mechanisms of cancer drug resistance involves reducing drug accumulation 
by enhancing efflux. Members of the ATP-binding cassette (ABC) transporter family proteins enable 
this efflux and are important, well-studied regulators at the plasma membranes of healthy cells. ABC 
transporters  are  transmembrane  proteins  present  not  only  in  human  cells,  but  in  all  extant  phyla, 
functioning to transport a variety of substances across cellular membranes. Though a transporter’s 
structure varies from protein to protein (e.g., there are 49 known members of the ABC family in humans), 
they are all classified by the presence of two distinct domains—a highly conserved nucleotide binding 
domain  and  a  more  variable  transmembrane  domain.  [36]  When  a  given  substrate  binds  to  the 
transmembrane domain, ATP hydrolysis at the nucleotide binding site drives a change in conformation Cancers 2014, 6  1775 
 
that pushes the substrate out of the cell. This efflux mechanism plays an important role in preventing 
over  accumulation  of  toxins  within  the  cell  [37].  Not  surprisingly,  ABC  transporters  are  highly 
expressed in the epithelium of the liver and intestine, where the proteins protect the body by pumping 
drugs and other harmful molecules into the bile duct and intestinal lumen. They also play a large role 
in maintaining the blood-brain barrier [38,39]. 
While efflux via ABC transporters is a normal physiological process, it is also a known mechanism 
of  drug  resistance  in  cancer  cells.  Three  transporters—multidrug  resistance  protein  1  (MDR1), 
multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein (BCRP)—are 
implicated in many drug resistant cancers. All three transporters have broad substrate specificity and 
are able to efflux many xenobiotics, including vinca alkaloids, epipodophyllotoxins, anthracyclines, 
taxanes,  and  kinase  inhibitors,  from  cells.  Thus,  they  protect  cancer  cells  from  many  first  line 
chemotherapies. MDR1, which produces Pgp, was the first of these to be identified and has been 
studied extensively [40–42]. Normal expression of the MDR1 gene in the colon, liver, and kidney is 
increased when these tissues become cancerous. Interestingly, in one study it was shown that treatment 
with  doxorubicin  induced  a  large  increase  in  MDR1  expression  in  lung  cancer  cells,  while  no 
significant change in expression was observed in normal lung cells [43], suggesting that there are both 
intrinsic and acquired mechanisms of MDR1 over-expression. Tissues that do not normally express 
MDR1, such as lung, breast, and prostate cells, are often drug resistant due to the expression of the 
related  transporters  MRP1  or  BCRP.  BCRP  protects  normal  cells  from  the  effects  of  toxins  like 
xenobiotics, maintains heme and folate homeostasis, and is expressed in stem cells. Many studies in 
various types of cancer have shown that increased expression of either of these transporters in tumor 
cells confers poor clinical outcomes. In one study of neuroblastoma, it was found that high levels of 
MRP1 expression were significantly correlated with poor clinical outcomes [44]. Similarly, expression 
of BCRP was predictive of drug response and survival rates in small cell lung cancer patients. It is 
sometimes possible to decrease drug efflux with the use of a BCRP inhibitory drug, such as Gefitinib. 
This particular drug is a tyrosine kinase inhibitor that functions to block the transporter function of 
BCRP, reversing drug resistance [45]. While few compounds have been identified to directly inhibit 
BCRP, it is clear that estrogen plays a large role in regulating its expression. One study showed that 
17b estradiol down-regulates the expression of BCRP in breast cancer cells, thereby increasing the 
concentration  of  chemotherapeutic  drugs  in  the  cancer  cells  [46].  Overall,  inhibition  of  these 
transcripts may help to sensitize cancer cells to drug treatments. 
As mentioned previously, the constitutive activation of signaling molecules like kinases drives the 
cell cycle out of control and results in cancer. Additionally, these proteins also regulate Pgp expression 
and can thereby modulate the environment to enable the development of drug resistance. Estrogen 
down-regulates the protein synthesis of Pgp in ER-positive breast cancer cells but not in ER-negative 
breast cancer cells or doxorubicine resistant ER-negative ovarian cancer cells [47,48]. Conversely, 
over-expression of proteins involved in the MAPK pathway, such HRas, c-Raf, MEK1/2, ERK1/2, 
which act downstream of receptor tyrosine kinases, increases the expression of Pgp. While inhibitors 
of the extracellular signal-regulated kinases (ERK) pathway down-regulate Pgp expression, growth 
factors like EGF and FGF increase it [49]. Interestingly, inhibition of HSP90, a chaperone protein that 
stabilizes many signaling proteins, also down-regulates Pgp [50]. Overall, these results suggest that 
Pgp  expression  and  stability  are  tightly  regulated  and  advantageous  to  tumor  cell  progression. Cancers 2014, 6  1776 
 
Targeting these oncogenic kinases that are often activated in cancers may be useful in reducing Pgp 
expression and sensitizing cancer cells to other drugs. 
2.4. DNA Damage Repair 
The  repair  of  damaged  DNA  has  a  clear  role  in  anticancer  drug  resistance.  In  response  to 
chemotherapy drugs that either directly or indirectly damage DNA, DNA damage response (DDR) 
mechanisms can reverse the drug-induced damage. For example, platinum-containing chemotherapy 
drugs such as Cisplatin cause harmful DNA crosslinks, which can lead to apoptosis. However, resistance 
to platinum-based drugs often arises due to nucleotide excision repair and homologous recombination, 
the  primary  DNA  repair  mechanisms  involved  in  reversing  platinum  damage  [51–53].  Thus,  the 
efficacy  of  DNA-damaging  cytotoxic  drugs  depends  on  the  failure  of  the  cancer  cell’s  DDR 
mechanisms. Inhibition of repair pathways used in conjunction with DNA damaging chemotherapy 
could sensitize cancer cells and therefore increase efficacy of the therapy. 
The therapeutic potential of targeting DDR mechanisms is especially exciting due to the prevalent 
dependence of cancers on a compensatory repair mechanism. Dysregulation or impairment of certain 
DDR  genes  and  mechanisms  either  by  mutations  or  epigenetic  silencing  are  common  in  many  
cancers  [54–56].  However,  other  DDR  mechanisms  can  be  up-regulated  to  compensate  for  the 
dysfunctional pathways. Although increased DNA repair activity can lead to increased resistance, this 
compensation also provides two opportunities for chemotherapy. First, targeting the overactive DDR 
pathway with chemotherapeutic drugs could leave cancers especially vulnerable to DNA-damaging 
drugs.  Alternatively,  knowledge  of  the  dysfunctional  DDR  could  allow  proper  prescription  of  a  
DNA-damage causing drug, which induces damage only repaired by the defective pathway. In both 
chemotherapy strategies, it is essential to identify the over-active and under-active DDR mechanisms. 
The DNA repair via O6-methylguanine DNA methyltransferase (MGMT) illustrates many of the 
challenges and promises of targeting DDR pathways for anticancer therapy. Some chemotherapy drugs 
induce guanine O6 alkylation. MGMT repairs such  an  alkylated nucleotide, converting  it back  to 
guanine before mismatch can occur. Over-expression of MGMT has been shown to protect hematopoietic 
stem cells from alkylating agents [57]. However, many tumors also have high MGMT levels [58], 
yielding them resistant to alkylating agents. Inhibiting this DDR mechanism could therefore prevent 
resistance and make cancer cells more vulnerable to alkylating agents. 
Although drugs targeting MGMT have been developed, few have shown much promise, and none 
are FDA approved [54]. In addition to only marginal clinical efficacy, some of these drugs also show 
toxicity due to a lack of specificity for cancer cells.  Accordingly, drugs currently in trial such as  
O6-benzylguanine sensitize healthy cells to cytotoxic drugs [54,59,60]. One possible way to avoid this 
problem could be to individualize chemotherapy by identifying MGMT promoter CpG methylation as a 
biomarker for increased sensitivity to O6-guanine alkylating agents. MGMT promoter methylation is 
often clinically associated with uncertain prognosis due to the genomic instability caused by silencing 
a DDR mechanism. However, studies also show that many glioma patients with epigenetically silenced 
MGMT genes have increased disease-free and overall survival rates [61]. The role of methylation in 
regulating MGMT is further discussed in the epigenetics section. Cancers 2014, 6  1777 
 
2.5. Cell Death Inhibition 
Cell  death  by  apoptosis  and  autophagy  are  two  important  regulatory  events.  Although  these 
processes  are  antagonistic  to  one  another,  they  both  contribute  to  cell  death.  Apoptosis  has  two 
established  pathways:  an  intrinsic  pathway  mediated  by  the  mitochondria  that  involves  B-cell 
lymphoma 2 (BCL-2) family proteins, caspase-9 and Akt, and an extrinsic pathway that involves death 
receptors on the cell surface. The intrinsic and extrinsic pathways merge through the activation of 
down-stream caspase-3, which ultimately causes apoptosis. However, there is also additional cross-talk 
between the pathways. 
In several types of cancers, BCL-2 family proteins, Akt, and other antiapototic proteins are highly 
expressed and down-stream transcription modulators like NF-κB and STAT are highly active, making 
these  good  targets  for  drug  development.  Recombinant  forms  of  tumor  necrosis  factor  related 
apoptosis-inducing ligand (TRAIL) and agonistic antibodies to these receptors can induce apoptosis 
through the activation of caspase-8. Clinical trials with TRAIL failed to produce significant results, but 
TRAIL in combination with other cytotoxic drugs is showing promise [62,63]. Several other drugs, 
including BCL-2 family inhibitors, histone deacetylase inhibitors (HDACi), protease inhibitors, and 
kinase inhibitors, are also showing promise in recent drug trials [14,63–66]. In fact, many new BCL-2 
family protein inhibitors are effective in inducing apoptosis in cancer cells, but prolonged use can 
produce resistance. Additionally, it has been shown that HDACi sensitize breast cancer cells to TRAIL 
in a mouse model [63] and to a protease calpain inhibitor in cell cultures [64]. Moreover, in two 
different  studies  it  was  shown  that  HDACi  sensitize  ovarian  cancer  cells  to  the  telomere  analog  
GT-oligo, and GT-oligo sensitizes ovarian cancer cells to TRAIL [65,66]. Many cancer drugs also 
induce apoptosis via the activation of c-Jun N-terminal kinases (JNK), which is downstream of the 
MAPK pathway. TRAIL induces apoptosis through JNK activation [65,66], and inhibition of the JNK 
signaling pathway leads to a decrease in cisplatin-induced apoptosis. All of these results suggest that 
cancer cells, including those which are drug resistant, can be effectively treated by using one drug that 
makes the cells susceptible to death through the altered expression or regulation of cell death pathway 
members in combination with another cytotoxic drug that kills the cells in their vulnerable states. 
HDACi are epigenetic drugs, and the implications of using these types of drugs as synergistic agents  
to sensitize normal and drug-resistant cancer cells is discussed further in the epigenetic section of  
this review. 
Autophagy  is  caused  by  phagolysosomal  death  in  an  acidic  lysosomal  pH.  Drugs  such  as 
chloroquine and its derivatives prevent this process by raising the pH to inactivate digestive enzymes 
in lysosomes. These drugs have primarily been used in the treatment of malaria, but they have also 
been shown to be beneficial in sensitizing cancer cells to other drugs. For instance, fluorouracil in 
combination with chloroquine is more effective at treating cancer cells than fluorouracil alone [67]. 
Additionally, hydroxychloroquine, a derivative of chloroquine, has been shown to inhibit autophagy in 
cancer cells and restore sensitivity to ER pathway inhibitors, such as tamoxifen, in ER-positive cancer 
cells [68]. Overall, chloroquine is thought to play a role in inhibiting autophagy-dependent resistance 
to chemotherapy [67], which makes it especially important in the field of drug-resistant cancers. These 
examples and the roles of apoptosis and autophagy in cancer drug resistance have been extensively 
discussed elsewhere [14]. Cancers 2014, 6  1778 
 
2.6. Epithelial-Mesenchymal Transition and Metastasis 
The epithelial to mesenchymal transition (EMT) is a mechanism by which solid tumors become 
metastatic. Metastasis itself is a complex phenomenon that includes changes in a cancer cell and the 
stromal cells that make up its environment. It also includes angiogenesis, which is the formation of 
new blood vessels around metastatic tumors. During EMT, cells within a tumor reduce the expression 
of cell adhesion receptors, including integrins and cadherins, which help in cell-cell attachment, and 
increase  the  expression  of  cell  adhesion  receptors  that  induce  cell  motility.  Cell  motility  is  also 
dependent on cytokines and chemokines, which may be released by cells in the microenvironment of 
tumors or by the tumors themselves. Additionally, higher expression of metalloproteases on the surface 
of tumors helps to clear the road for the cells to move outward, promoting metastasis. The role of EMT 
in cancer drug resistance is an emerging area of research [69,70]. 
Recent  articles  point  toward  the  involvement  of  cancer  progenitor  cells,  which  are  sometimes 
referred to as cancer stem cells, in the formation of metastatic cancer cells, and this might explain why 
cancer can relapse at distant sites after apparently successful treatment and remission [71–75]. Death 
of these cancer progenitor cells via epigenetic drug treatment may be one way to prevent remote site 
metastasis. Several factors during EMT play significant roles in the development of drug resistance, but 
these are dependent on the metastatic grade of the tumor, which is defined as the level of differentiation 
and degree of EMT. For example, in ERBB2 (HER2) positive breast cancer, tumors that express high 
levels of β1 integrins develop more resistance to antibody inhibitors such as transtuzumab [76]. This 
finding reaffirms previous studies that found that the ligation of β1 integrins protects leukemia cells 
from drug induced cell death [77]. Additionally, integrin receptors and receptor tyrosine kinases need 
to associate in order for breast cancer to progress [78,79]. 
Drug resistance in cancer cells may also develop during the signaling processes of differentiation, 
which are essential for EMT. For example, the increased expression of integrin αvβ1 in colon cancer 
positively regulates transforming growth factor β (TGFβ) expression, which is required for EMT, and 
it further serves as a survival signal for cancer cells against drugs [80]. Integrin αvβ1 interacts with 
stromal cell adhesion molecules to convey such signals [80]. Similarly, β3 integrin and src regulate 
TGFβ mediated EMT in mammary cancer [81]. Ligation of integrin β1 provides proliferative and 
survival signal-mediated FAK kinase in lung cancers [82]. Autocrine signaling provided by vascular 
endothelial growth factor (VEGF) and Flt-1 help the cancer cell survival process [80]. Selectin and 
other cell adhesion receptors, which interact with the extracellular matrix and cell adhesion receptors 
of stromal cells, also participate in the process of EMT and cell survival [83–87] (Figure 2). The 
differentiation  process  during  EMT  generates  more  metastatic  cancer  cells  with  different  cellular 
morphology,  which  needs  cytoskeletal  re-arrangement  [88].  Recent  studies  suggest  a  possible 
connection of actin binding protein L-plastin in colon cancer progression and prognosis [89]. T-plastin 
is implicated in the progression of lymphomas and their drug resistance [90]. Cancers 2014, 6  1779 
 
Figure 2. Depiction of the primary mechanisms that enable cancer cells to become drug 
resistant. These  include  drug  inactivation, alteration of drug  targets, drug  efflux,  DNA 
damage repair, inhibition of cell death, EMT, and epigenetic effects. In the case of EMT, 
stromal cells assist in this process and signal for improved drug resistance in cancer cells. 
Cell adhesion molecules on stromal cells and extracellular matrix proteins attach to the cell 
adhesion molecules on cancer cells. Stromal cells and cancer cells also secrete factors that 
regulate EMT. The depiction displays a simplified example of these cell interactions. 
 
The  role  of  stromal  cells  in  causing  drug  resistance  has  also  been  investigated.  B-Raf  is  an 
intermediate  kinase  in  the  down-stream  signaling  pathway  initiated  by  receptor  tyrosine  kinases. 
Resistance against B-Raf inhibitor drugs was observed in melanoma cells when they were co-cultured 
with  fibroblast  cells  [91],  indicating  that  stromal  cells  may  influence  the  development  of  drug 
resistance. This is one reason why so many drugs fail clinical trials in in vivo animal models despite 
high efficacy against cancer in cell cultures. 
EMT  and  cancer  metastasis  involve  numerous  variables.  Metastatic  cancer  cells  are  often  a 
heterogeneous population, in which cell differentiation is not uniform. This difference is one of the 
reasons why some patients are more responsive to treatments than the other. It appears that EMT, 
while  favoring  the  formation  of  more  metastatic  cancer  cells,  also  provide  signals  for  increasing 
survival which may cause drug resistance in some if not all the cells present in a tumor. Since this is a 
very complex and dynamic mechanism, thorough investigation is necessary to fully understand each 
step in the regulation of drug action and thus, drug resistance. 
2.7. Cancer Cell Heterogeneity 
In addition to the development of drug resistance in cancer progenitor cells and adult cancer cells by 
the  mechanisms  previously  discussed,  another  aspect  of  cancer  relapse  is  the  enrichment  of  drug 
resistant cancer cells already present in the heterogeneous cancer cell population. Recent studies show 
that a fraction of cells within this heterogeneous population have stem cell properties and are usually Cancers 2014, 6  1780 
 
drug resistant. In addition, another small fraction of adult cancer cells also possess drug resistance 
capabilities. The treatment of cancers, by definition, kills only drug sensitive cancer cells, and thus the 
drug resistance cancer cells survive and can expand and contribute to pathology over time. Some of 
these resistant cancers cells may be in the circulation and can form tumors in distant organs. However, 
heterogeneity is observed in cancer cells both in circulation and in solid tumors. 
A recent study on acute myeloid leukemia determined two coexisting dominant clones. One was 
drug sensitive and the other drug resistant. It is possible that re-occurrence of this disease in patients 
after successful therapy may be the result of cancer cell growth from the drug resistant clone [92]. This 
possibility exists in all forms of cancer, as all tumors are heterogeneous, due to aberrant DNA repair 
mechanisms  and  cell  death  pathway  dysregulation.  A  clonal  composition  study  of  breast  cancer 
revealed that breast cancers may have monogenomic or multiple genomic tumors [93]. Polygenomic 
tumors contain many different types of clonal subpopulations, all of which may have different drug 
sensitivities and resistance characteristics [93]. 
An  analysis  of  pancreatic  cancer  samples  showed  that  tumor  progression  involves  telomere 
dysfunction  and  cell  cycle  deregulation  and  that  these  changes  occur  in  the  early  stage  of 
carcinogenesis [94]. However, the metastatic process is not as well defined, and with heterogeneity as 
an outcome, the possibility of different drug sensitivities and drug resistance characteristics among 
clonal subpopulations arises [94]. Taken together, the drug resistance of cancer progenitor cells and the 
acquired drug resistance of cancer cells following EMT or other mechanisms pose a very complex 
challenge for the development of better therapies to reduce the relapse of cancers. 
3. Role of Epigenetics in Cancer Drug Resistance 
An important set of mechanisms that cause resistance to cancer treatment and that have not been 
readily discussed are epigenetic modifications, which can also influence carcinogenesis. The two main 
types  of  epigenetic  changes  are  DNA  methylation  and  histone  modification  via  acetylation  or 
methylation. DNA methylation consists of methyl groups binding to cytosines at CG-dinucleotides 
within regions known as CpG islands, primarily found in upstream gene promoter regions. However, 
methylation can occur at other loci throughout the genome. Conversely, histone modifications alter 
chromatin conformation. For example, histone acetylation opens the chromatin, while deacetylation 
closes it. These mechanisms ultimately regulate the expression of genes throughout the chromosome, 
and  in  cancer,  this  normal  regulation  is  broken.  For  example,  tumor  suppressor  genes  are  often 
silenced  via  hypermethylation,  and  oncogenes  are  over-expressed  via  hypomethylation.  However, 
epigenetic mechanisms are usually reversible, and researchers may be able to take advantage of this 
opportunity to develop treatments that can counteract drug resistant cancers. 
This  review  initially  focused  on  how  established  mechanisms  cause  resistance  in  cancer  cells. 
Interestingly, many of these well-studied mechanisms may also be influenced by epigenetic changes. 
More recent studies suggest that epigenetic alterations, such as histone methylation and acetylation, 
may play a role in the development of drug resistance. One study proposed that hypermethylation of 
the MDR1 promoter is associated with transcriptional repression and chromatin structural changes [95]. 
Others have also suggested that DNA methylation is associated with acquired multidrug resistance. In 
experiments expanding on this idea, demethylation of the MDR1 promoter in cancer cell lines was Cancers 2014, 6  1781 
 
found to be strongly associated with the acquisition of a multidrug resistant phenotype [96]. Overall, 
methylation at this promoter controls MDR1 transcription, increases drug resistance, and decreases drug 
accumulation, making it an excellent target for epigenetic treatment. Specifically, anti-methylation drugs 
might be useful in sensitizing multidrug resistant cancer cells to other types of drugs. 
Epigenetic  mechanisms  can  also  influence  DNA  damage  repair.  For  example,  DNA  mismatch 
repair processes can be lost due to hypermethylation of the human mutL homolog 1 (hMLH1) gene 
promoter, and this can lead to cancer development. In one study, tumor-bearing mice were treated with 
nontoxic doses of the demethylating agent 2-deoxy-5-azacytidine (DAC). While the re-expression of 
hMLH1 is associated with a decrease in hMLH1 promoter methylation, the DAC treatment was not 
found to have an effect on the rate of tumor growth. However, it did sensitize the tumors to other 
drugs, including cisplatin, carboplatin, temozolomide, and epirubicin [97]. DAC may have a role in 
increasing  the  efficacy  of  chemotherapy  for  patients  with  tumors  characterized  by  high  hMLH1 
promoter  methylation  and  low  hMLH1  expression.  Similarly,  another  experiment  showed  that 
demethylation  of  the  hMLH1  promoter  by  DAC  restores  mismatch  repair  proficiency  and  drug 
sensitivity to 5-fluorouracil in colorectal cancer cells [98]. 
The DNA repair enzyme MGMT inhibits the killing of tumor cells by alkylating chemotherapy 
agents. Methylation of MGMT causes gene silencing and decreased MGMT production. Epigenetic 
alteration of MGMT expression has been associated with a modified chromatin configuration. Cells can 
acquire resistance to N-methyl-N-nitrosurea, a methylating chemotherapy agent, by either reactivating a 
previously silenced MGMT gene, or by repressing the hMSH6 mismatch repair gene. The number of 
active MGMT molecules at the time of methylation determines the capacity of a cell for MGMT 
repair.  Treatment  with  chemical  methylating  agents  alters  gene  expression  patterns  by  increasing 
genomic DNA methylation, which ultimately leads to increased repair or tolerance of O6-methylguanine 
and  the  emergence  of  chemotherapy  resistance  [99].  Other  researchers  have  studied  gliomas  to 
determine  whether  MGMT  promoter  methylation  is  related  to  the  responsiveness  of  a  tumor  to 
alkylating agents, and found that this methylation was associated with tumor regression and prolonged 
survival rates [100]. 
Human breast cancer cells can also exhibit drug resistance via epigenetic mechanisms. For example, 
methotrexate resistance in MDA-MB-231 breast cancer cells is caused by an inherent defect in drug uptake 
and a lack of reduced folate carrier (RFC) expression. In one study, the treatment of MDA-MB-231 
cells with the DNA methylation inhibitor DAC improved methotrexate uptake but also restored RFC 
expression, which promoted methotrexate efflux. These results suggest that DAC counteracts some 
methotrexate-resistance  mechanisms  while  improving  others  [101].  In  another  study,  an  inverse 
relationship was found between tamoxifen resistance and methylation of the ERβ gene. In general, 
tamoxifen-resistant tumors showed denser ERβ gene methylation than control tumors [102]. 
Epigenetically mediated forms of drug resistance are also observed in other cancers. For instance, 
melanoma cells, which are notoriously unresponsive to chemotherapy, can acquire resistance to the 
chloroethylating drug fotemustine. One study determined that this acquired resistance is associated 
with high MGMT activity and that the MGMT gene in fotemustine resistant cells was hypermethylated. 
However, these cells were effectively sensitized when treated with DAC [103]. Additionally, some 
prostate cancers exhibit androgen resistance that may be due to transcriptional inactivation of the 
androgen receptor gene caused by DNA methylation. Cytosine DNA methyltransferase inhibitors have Cancers 2014, 6  1782 
 
been found to restore androgen responsiveness in androgen-refractory tumor cells, though, and these 
cells are then responsive to growth inhibition by anti-androgens [104]. Overall, epigenetic alterations 
have been increasingly recognized as a cause of drug resistance in many different kinds of cancer. 
Thus, epigenetic therapy could be utilized as a priming therapy to sensitize drug-resistant cancer cells 
in conjunction with conventional and targeted chemotherapy. 
In addition to the development of drug resistance, epigenetics plays a significant role in cancer 
progenitor cell (or cancer stem cell) formation and cancer progression [73,74]. Cancer progenitor cells 
are not killed by conventional cancer therapies and are a major cause of cancer relapse. Addressing this 
problem could reduce relapse as well as provide a means by which to handle drug resistant cancer 
cells. Thus, this is an important topic to consider. Cancer progenitor cell formation  is a  complex 
process. The current paradigm suggests that a combination of environmental and genetic changes, such 
as random mutations, increased signaling processes, stromal influences, hormonal imbalances, and 
germ-line mutations make adult and stem cells susceptible to progenitor cell formation. However, it is 
reasonable to suspect that a common trigger ignites the progression of these susceptible cells, and we 
have  proposed  that  epigenetic  alterations  may  serve  as  this  common  trigger  to  stimulate  the 
development of normal cells with a cancer predisposition into cancer progenitor cells [73,74]. For 
example,  MDR1  expression  increases  in  early  cancer  progenitor  cells  of  the  myeloid  lineage.  
Over-expression of MDR1 was also found to be associated with the expression of CD34 antigen, a 
marker  for  progenitor  cells  of  this  lineage.  Interestingly,  this  correlation  was  observed  in 
myelodysplasias  and  myeloblast  leukemia  [16].  Cancer  cells  are  opportunistic  in  silencing  tumor 
suppressor genes by methylation, increasing expression of telomeres by methylation, and enhancing 
the  expression  of  oncogenes  by  hypomethylation.  These  are  the  characteristics  which  may  drive 
predisposed stem cells to form cancer progenitor cells. This idea is partially supported by the fact that 
cancer progenitor cells are usually drug resistant. Higher expression of the MDR1 gene could be one 
mechanism by which they acquire drug resistance. In contrast, mature leukemia cells are drug sensitive 
and show low levels of MDR1 expression. However, mature leukemia cells may have a population of 
cancer progenitor cells that highly express MDR1, and this MDR1 expression again increases when 
these cells become drug resistant. As discussed, epigenetics can regulate the expression of the MDR1 
gene, and this reversible epigenetic mechanism could be a prime target for drug therapies. 
Reversing the epigenetic changes that assist in cancer progenitor cell formation should effectively 
kill  these  cells  and  should  consequently  stop  tumor  growth  and  decrease  the  chance  of  relapse. 
Tumorigenesis requires metastatic potential, and cell differentiation is essential for the stage-specific 
formation of increasingly metastatic tumor forms or grades. Since cell growth must slow down before 
a cell differentiates, we have proposed that epigenetic switches, which can simultaneously enhance 
differentiation  and  repress  growth,  regulate  the  stage-specific  development  of  more  metastatic  
cancer [73–75]. Therefore, epigenetic modifications may also play a key role in tumor formation and 
tumor metastasis, further making them ideal targets for therapy in the context of drug resistance. 
Theoretically, a combination of epigenetic drugs with conventional chemotherapy should be more 
effective in treating tumors and drug resistant cancers. Several recent studies have shown encouraging 
results to support this hypothesis [73–75]. One study has shown that HDACi treatment demethylates 
and re-expresses tumor suppressor genes [105], leading to the sensitization of cancer cells to other 
cytotoxic drugs. Additionally, HDACi in combination with the calpain protease inhibitor calpeptin has Cancers 2014, 6  1783 
 
been shown to enhance growth inhibition of breast and ovarian cancer cells [64,106]. Furthermore, the 
combination of HDACi and TRAIL in mouse models was found to reduce tumor size by inducing 
apoptosis [37], and the combination of HDACi and GT-oligo increases ovarian cancer cell death [65]. 
We have proposed that demethylation and re-expression of tumor suppressor genes render cancer cells 
susceptible  to  other  cytotoxic  drugs  [73–75,107].  Drug  resistant  cancer  cells  may  be  similarly 
sensitized by demethylation to other cytotoxic agents as well. Recent clinical studies suggest that 
pretreatment with epigenetic drugs can reduce cancer relapse and be more effective for treating drug 
resistant cancers [108]. For example, one study determined that lung cancer patients who were treated 
with the epigenetic drugs DAC and HDACi prior to conventional chemotherapy had lower incidences 
of relapse [108]. Two other studies demonstrated that MAPK pathway inhibitors in combination with 
HDACi  suppressed  cAMP  mediated  resistance  in  melanoma  cells  [109]  and  that  pre-treatment  of 
platinum drug resistant ovarian cancer cells with HDACi and methylation inhibitors sensitized these 
cells to cisplatin-mediated cell death [110]. In this last study, epigenetic drug treatment resulted in the 
re-expression of RGS10, an important regulator of cell survival and chemoresistance in ovarian cancer. 
Hypermethylation and histone deacetylation silences this gene in drug resistant ovarian cancer cells, 
and re-expression of this gene made these cells susceptible to platinum drugs. Overall, these results 
indicate that pretreatment using epigenetic drugs in combination with conventional therapies may be 
beneficial  for  reducing  cancer  relapse  and  improving  drug  resistant  cancer  treatment.  The  role  of 
epigenetic drugs in treating a myriad of diseases has been discussed extensively elsewhere [111,112] 
and is an important area of research to be further pursued. 
4. Conclusions 
Cancer drug resistance is a complex phenomenon that is influenced by drug inactivation, drug target 
alteration, drug efflux, DNA damage repair, cell death inhibition, EMT, inherent cell heterogeneity, 
epigenetic  effects,  or  any  combination  of  these  mechanisms.  The  current  paradigm  states  that 
combination therapy should be the best treatment option because it should prevent the development of 
drug resistance and be more effective than any one drug on its own [73–75,107,111,112]. Therefore, 
such treatment regimens should be considered and developed to counteract the increasing prevalence 
of drug resistance in cancers. Cancer progenitor cells are often drug resistant as well. These progenitor 
cells can persist in patients seemingly in remission, and they are able to remain stationary or migrate to 
other sites during metastasis. Thus, cancer progenitor cells can cause cancer relapse at the original 
tumor site or in distant organs. The next step in anticancer therapy development should target the 
elimination of such cancer progenitor cells. Additionally, the existence of a small population of drug 
resistant cancer cells poses another complexity that is difficult to address [92–94]. These drug resistant 
cancer  cells  also  contribute  to  cancer  relapse  after  apparent  remission.  It  will  be  interesting  to 
determine  how  much  contribution  cancer  progenitor  cells  or  drug  resistant  cancer  cells  render  to 
generate drug resistance. Therefore, it is important to continue efforts to understand the underlying 
mechanisms  of  cancer  drug  resistance  and  to  identify  therapies  that  can  treat  cancers  no  longer 
susceptible to current treatments. Epigenetic drugs may assist in this endeavor as they are thought to be 
capable  of  sensitizing  drug  resistant  cancer  cells  to  other  drugs  [73–75,107,111,112],  and  recent Cancers 2014, 6  1784 
 
studies have supported these propositions [108,110]. Further research in this direction is needed to 
improve overall understanding and treatment of drug resistant cancers. 
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